A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2020-04-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of
intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA
(BB-401) in patients with metastatic/recurrent HNSCC.